Associations of non-melanoma skin cancer and melanoma, extra-cutaneous cancers and smoking in adults: a US population-based study

2014 ◽  
Vol 29 (7) ◽  
pp. 1389-1397 ◽  
Author(s):  
J.I. Silverberg ◽  
D. Ratner
Keyword(s):  
Skin Cancer ◽  
Population Based ◽  
Population Based Study ◽  
Non Melanoma Skin Cancer ◽  
Melanoma Skin

Trends in incidence and survival analysis in non-melanoma skin cancer from 1994 to 2012 in Girona, Spain: A population-based study

2016 ◽  
Vol 45 ◽  
pp. 6-10 ◽  
Author(s):  
J. Rubió-Casadevall ◽  
A.M. Hernandez-Pujol ◽  
M.C. Ferreira-Santos ◽  
G. Morey-Esteve ◽  
L. Vilardell ◽  
...  
Keyword(s):  
Survival Analysis ◽  
Skin Cancer ◽  
Population Based ◽  
Population Based Study ◽  
Non Melanoma Skin Cancer ◽  
Melanoma Skin

scholarly journals A Population-based Study of DNA Repair Gene Variants in Relation to Non-melanoma Skin Cancer as a Marker of a Cancer-prone Phenotype

2012 ◽  
Vol 33 (9) ◽  
pp. 1692-1698 ◽  
Author(s):  
Ingo Ruczinski ◽  
Timothy J. Jorgensen ◽  
Yin Yao Shugart ◽  
Yvette Berthier Schaad ◽  
Bailey Kessing ◽  
...  
Keyword(s):  
Dna Repair ◽  
Skin Cancer ◽  
Population Based ◽  
Gene Variants ◽  
Repair Gene ◽  
Population Based Study ◽  
Non Melanoma Skin Cancer ◽  
Dna Repair Gene ◽  
Melanoma Skin

A randomized trial of selenium and vitamin E for primary prevention of non-melanoma skin cancer: Trial results and experience from a low-resource setting.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 1511-1511 ◽  
Author(s):  
Maria Argos ◽  
James J. Dignam ◽  
Faruque Parvez ◽  
Mahfuzar Rahman ◽  
Samar K Hore ◽  
...  
Keyword(s):  
Vitamin E ◽  
Primary Prevention ◽  
Skin Cancer ◽  
Beneficial Effect ◽  
Population Based ◽  
Cancer Trial ◽  
Low Resource ◽  
Non Melanoma Skin Cancer ◽  
Related Mortality ◽  
Melanoma Skin

1511 Background: Selenium and vitamin E supplementation previously have shown some evidence of a beneficial effect in the secondary prevention of non-melanoma skin cancer (NMSC). More than 100 million people worldwide are at increased risk of NMSC and other cancers due to arsenic exposure from drinking water and diet – a risk that persists for several decades even after the exposure has terminated. Here, we report on the design, methods and main results of the Bangladesh Vitamin E and Selenium Trial (BEST) – a population-based chemoprevention study conducted among 7,000 adults with visible arsenic toxicity. Methods: BEST is a 2 × 2 full factorial, double-blind, randomized placebo controlled trial of 7,000 adults having manifest arsenical skin lesions evaluating the efficacy of 6-year supplementation with alpha-tocopherol (100 mg daily) and L-selenomethionine (200 μg daily) for the prevention of NMSC incidence. Results: Excellent compliance was maintained through the course of the trial, based on data from pill counts, self-reported compliance, and bioadherence. Among participants on treatment through the end of the 6-year intervention period, > 85% were adherent to at least 80% of study supplements. More than 500 new NMSC cases were ascertained using a three-tiered biopsy protocol. No significant beneficial effects were observed on NMSC incidence during the study period for selenium or vitamin E. Among more than 500 observed deaths (including 182 cancer-related deaths), there were also no significant treatment effects on total mortality, cancer-related mortality or arsenical cancer-related mortality. Conclusions: This large population-based trial does not support any beneficial effect of vitamin E or selenium supplementation for the primary prevention of NMSC or mortality in an arsenic-exposed population. With the rapidly increasing burden of preventable cancers in low- and middle-income countries, efficient and feasible chemoprevention study designs and approaches, such as employed in Bangladesh, may prove impactful in conceiving large scale cancer chemoprevention trials in low-resource settings. Clinical trial information: NCT00392561.

scholarly journals Non-melanoma Skin Cancer and Ten-year All-cause Mortality: A Population-based Cohort Study

2010 ◽  
Vol 90 (4) ◽  
pp. 362-367 ◽  
Author(s):  
A Jensen ◽  
AL Lamberg ◽  
JB Jacobsen ◽  
A Braae Olesen ◽  
HT Sørensen
Keyword(s):  
Cohort Study ◽  
Skin Cancer ◽  
Population Based ◽  
Non Melanoma Skin Cancer ◽  
All Cause Mortality ◽  
Melanoma Skin

scholarly journals Photosensitizing Agents and the Risk of Non-Melanoma Skin Cancer: A Population-Based Case–Control Study

2013 ◽  
Vol 133 (8) ◽  
pp. 1950-1955 ◽  
Author(s):  
Sarah N. Robinson ◽  
Michael S. Zens ◽  
Ann E. Perry ◽  
Steven K. Spencer ◽  
Eric J. Duell ◽  
...  
Keyword(s):  
Skin Cancer ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Non Melanoma Skin Cancer ◽  
Photosensitizing Agents ◽  
Control Study ◽  
Melanoma Skin

scholarly journals Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study

Rheumatology ◽  
2018 ◽  
Vol 58 (4) ◽  
pp. 683-691 ◽  
Author(s):  
François Montastruc ◽  
Christel Renoux ◽  
Sophie Dell’Aniello ◽  
Teresa A Simon ◽  
Laurent Azoulay ◽  
...  
Keyword(s):  
Cohort Study ◽  
Skin Cancer ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Non Melanoma Skin Cancer ◽  
Increased Risk ◽  
Significant Difference ◽  
Specific Cancer ◽  
Risk Of Cancer ◽  
Melanoma Skin

Abstract Objective To assess whether abatacept as initial biological DMARD (bDMARD) in the treatment of RA, when compared with other bDMARDs, is associated with an increased risk of cancer overall and by specific cancer sites (breast, lung, lymphoma, melanoma and non-melanoma skin cancer). Methods We performed a population-based cohort study among patients newly treated with bDMARDs within the US-based Truven MarketScan population and Supplemental US Medicare from 2007 to 2014. Cox proportional hazards models were used to estimate hazard ratios and 95% CIs of any cancer (and specific cancers) associated with initiation of abatacept, compared with initiation of other bDMARDs, adjusted for age and deciles of the propensity score. Results The cohort included 4328 patients on abatacept and 59 860 on other bDMARDs, of whom 409 and 4197 were diagnosed with any cancer during follow-up (incidence rates 4.76 per 100 per year and 3.41 per 100 per year, respectively). Compared with other bDMARDs, the use of abatacept was associated with an increased incidence of cancer overall (hazard ratioadjusted 1.17; 95% CI 1.06, 1.30). Analyses by specific cancer sites showed a significantly increased incidence of non-melanoma skin cancer (hazard ratioadjusted 1.20; 95% CI 1.03, 1.39), but no significant difference for other specific cancer sites. Conclusion The use of abatacept as first bDMARD in the treatment of RA was associated with a slight increased risk of cancer overall and particularly non-melanoma skin cancer, compared with other bDMARDs. This potential signal needs to be replicated in other settings.

Sign in / Sign up

Export Citation Format

Share Document